{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:07:52Z","timestamp":1791486472282,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32GM136540"],"award-info":[{"award-number":["T32GM136540"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA278495"],"award-info":[{"award-number":["F30CA278495"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K00CA253687"],"award-info":[{"award-number":["K00CA253687"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA014051"],"award-info":[{"award-number":["P30-CA014051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1K22CA289207"],"award-info":[{"award-number":["1K22CA289207"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA300526"],"award-info":[{"award-number":["R37CA300526"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR240079"],"award-info":[{"award-number":["RR240079"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0108"],"award-info":[{"award-number":["HT9425-25-1-0108"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Genet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41588-026-02768-8","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:02:33Z","timestamp":1790758953000},"page":"2605-2618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2373-0172","authenticated-orcid":false,"given":"Nicolas","family":"Mathey-Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-130X","authenticated-orcid":false,"given":"Bing","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-975X","authenticated-orcid":false,"given":"Agata L.","family":"Patriotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"William M.","family":"Rideout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Murazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaedra","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7775-0606","authenticated-orcid":false,"given":"Milton R.","family":"Cornwall-Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan G.","family":"Heileman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Trakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla P.","family":"Concepcion-Crisol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0047","authenticated-orcid":false,"given":"Dian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5785-8911","authenticated-orcid":false,"given":"Tyler","family":"Jacks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2768_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2768_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560\u2013562 (2015).","journal-title":"Nat. Med."},{"key":"2768_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007).","journal-title":"Science"},{"key":"2768_CR4","first-page":"21","volume":"10","author":"VW Zhu","year":"2019","unstructured":"Zhu, V. W., Schrock, A. B., Ali, S. M. & Ou, S.-H. I. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. Lung Cancer 10, 21\u201326 (2019).","journal-title":"Lung Cancer"},{"key":"2768_CR5","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack, I. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26, 2535\u20132545 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR6","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).","journal-title":"Sci. Transl. Med."},{"key":"2768_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7377","volume":"6","author":"MJ Niederst","year":"2015","unstructured":"Niederst, M. J. et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015).","journal-title":"Nat. Commun."},{"key":"2768_CR8","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin. Cancer Res. 26, 2654\u20132663 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR9","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2768_CR10","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi, Y. et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin. Cancer Res. 26, 5962\u20135973 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2768_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"2768_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"2768_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"2768_CR14","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2768_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2768_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2026.01.001","volume":"44","author":"JM Riedl","year":"2026","unstructured":"Riedl, J. M. et al. Emerging landscape of KRAS inhibitors in cancer treatment. Cancer Cell 44, 471\u2013497 (2026).","journal-title":"Cancer Cell"},{"key":"2768_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka, N. et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation. Cancer Discov. 11, 1913\u20131922 (2021).","journal-title":"Cancer Discov."},{"key":"2768_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"2768_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong, X. et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell 42, 413\u2013428 (2024).","journal-title":"Cancer Cell"},{"key":"2768_CR20","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","volume":"15","author":"RY Ebright","year":"2025","unstructured":"Ebright, R. Y., Dilly, J., Shaw, A. T. & Aguirre, A. J. Response and resistance to RAS inhibition in cancer. Cancer Discov. 15, 1325\u20131349 (2025).","journal-title":"Cancer Discov."},{"key":"2768_CR21","doi-asserted-by":"publisher","first-page":"RP96992","DOI":"10.7554\/eLife.96992.3","volume":"13","author":"PC Ghazi","year":"2024","unstructured":"Ghazi, P. C. et al. Inhibition of ULK1\/2 and KRASG12C controls tumor growth in preclinical models of lung cancer. eLife 13, RP96992 (2024).","journal-title":"eLife"},{"key":"2768_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nature06030","volume":"448","author":"H Ji","year":"2007","unstructured":"Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807\u2013810 (2007).","journal-title":"Nature"},{"key":"2768_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4261","volume":"5","author":"X Han","year":"2014","unstructured":"Han, X. et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 5, 3261 (2014).","journal-title":"Nat. Commun."},{"key":"2768_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2018.11.027","volume":"127","author":"S Park","year":"2019","unstructured":"Park, S., Han, J. & Sun, J.-M. Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. Lung Cancer 127, 66\u201368 (2019).","journal-title":"Lung Cancer"},{"key":"2768_CR25","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1158\/2159-8290.CD-20-0442","volume":"10","author":"MP Zafra","year":"2020","unstructured":"Zafra, M. P. et al. An in vivo kras allelic series reveals distinct phenotypes of common oncogenic variants. Cancer Discov. 10, 1654\u20131671 (2020).","journal-title":"Cancer Discov."},{"key":"2768_CR26","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1073\/pnas.1319963111","volume":"111","author":"KD Sutherland","year":"2014","unstructured":"Sutherland, K. D. et al. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc. Natl Acad. Sci. USA 111, 4952\u20134957 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2768_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42156-y","volume":"14","author":"LM Blair","year":"2023","unstructured":"Blair, L. M. et al. Oncogenic context shapes the fitness landscape of tumor suppression. Nat. Commun. 14, 6422 (2023).","journal-title":"Nat. Commun."},{"key":"2768_CR28","doi-asserted-by":"publisher","first-page":"eadq6647","DOI":"10.1126\/scitranslmed.adq6647","volume":"18","author":"H-C Huang","year":"2026","unstructured":"Huang, H.-C. et al. Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models. Sci. Transl. Med. 18, eadq6647 (2026).","journal-title":"Sci. Transl. Med."},{"key":"2768_CR29","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1158\/0008-5472.CAN-05-2193","volume":"65","author":"EL Jackson","year":"2005","unstructured":"Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280\u201310288 (2005).","journal-title":"Cancer Res."},{"key":"2768_CR30","doi-asserted-by":"publisher","unstructured":"Li, Z. et al. Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma. Cancer Discov. 14, 308\u2013325 https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0289 (2024).","DOI":"10.1158\/2159-8290.CD-23-0289"},{"key":"2768_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41586-020-2922-4","volume":"587","author":"KJ Travaglini","year":"2020","unstructured":"Travaglini, K. J. et al. A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature 587, 619\u2013625 (2020).","journal-title":"Nature"},{"key":"2768_CR32","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.cell.2022.04.015","volume":"185","author":"D Yang","year":"2022","unstructured":"Yang, D. et al. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell 185, 1905\u20131923 (2022).","journal-title":"Cell"},{"key":"2768_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2020.06.012","volume":"38","author":"ND Marjanovic","year":"2020","unstructured":"Marjanovic, N. D. et al. Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell 38, 229\u2013246 (2020).","journal-title":"Cancer Cell"},{"key":"2768_CR34","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232\u20131251 (2020).","journal-title":"Cell"},{"key":"2768_CR35","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature09535","volume":"468","author":"DM Feldser","year":"2010","unstructured":"Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572\u2013575 (2010).","journal-title":"Nature"},{"key":"2768_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nature09526","volume":"468","author":"MR Junttila","year":"2010","unstructured":"Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567\u2013571 (2010).","journal-title":"Nature"},{"key":"2768_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919\u2013926 (2024).","journal-title":"Nature"},{"key":"2768_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature13898","volume":"517","author":"PMK Westcott","year":"2015","unstructured":"Westcott, P. M. K. et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 517, 489\u2013492 (2015).","journal-title":"Nature"},{"key":"2768_CR39","doi-asserted-by":"publisher","first-page":"E10947","DOI":"10.1073\/pnas.1708391114","volume":"114","author":"W-J Chung","year":"2017","unstructured":"Chung, W.-J. et al. Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. Proc. Natl Acad. Sci. USA 114, E10947\u2013E10955 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2768_CR40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/gcc.20296","volume":"45","author":"A Sweet-Cordero","year":"2006","unstructured":"Sweet-Cordero, A. et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer 45, 338\u2013348 (2006).","journal-title":"Genes Chromosomes Cancer"},{"key":"2768_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Molecular characterization of acquired resistance to KRASG12C\u2013EGFR inhibition in colorectal cancer. Cancer Discov. 13, 41\u201355 (2023).","journal-title":"Cancer Discov."},{"key":"2768_CR42","doi-asserted-by":"publisher","first-page":"e164413","DOI":"10.1172\/JCI164413","volume":"133","author":"M Salm\u00f3n","year":"2023","unstructured":"Salm\u00f3n, M. et al. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. J. Clin. Invest. 133, e164413 (2023).","journal-title":"J. Clin. Invest."},{"key":"2768_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08200-y","volume":"10","author":"V Deshpande","year":"2019","unstructured":"Deshpande, V. et al. Exploring the landscape of focal amplifications in cancer using AmpliconArchitect. Nat. Commun. 10, 392 (2019).","journal-title":"Nat. Commun."},{"key":"2768_CR44","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1002\/1878-0261.13213","volume":"16","author":"G Paniagua","year":"2022","unstructured":"Paniagua, G. et al. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Mol. Oncol. 16, 3066\u20133081 (2022).","journal-title":"Mol. Oncol."},{"key":"2768_CR45","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"2768_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22817-6","volume":"12","author":"DR Little","year":"2021","unstructured":"Little, D. R. et al. Differential chromatin binding of the lung lineage transcription factor NKX2-1 resolves opposing murine alveolar cell fates in vivo. Nat. Commun. 12, 2509 (2021).","journal-title":"Nat. Commun."},{"key":"2768_CR47","doi-asserted-by":"publisher","first-page":"20545","DOI":"10.1073\/pnas.1906663116","volume":"116","author":"DR Little","year":"2019","unstructured":"Little, D. R. et al. Transcriptional control of lung alveolar type 1 cell development and maintenance by NK homeobox 2-1. Proc. Natl Acad. Sci. USA 116, 20545\u201320555 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2768_CR48","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards, A. C. et al. TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 83, 4112\u20134129 (2023).","journal-title":"Cancer Res."},{"key":"2768_CR49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"2768_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","volume":"25","author":"CG Kinsey","year":"2019","unstructured":"Kinsey, C. G. et al. Protective autophagy elicited by RAF\u2009\u2192\u2009MEK\u2009\u2192\u2009ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat. Med. 25, 620\u2013627 (2019).","journal-title":"Nat. Med."},{"key":"2768_CR51","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ng.3218","volume":"47","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47, 250\u2013256 (2015).","journal-title":"Nat. Genet."},{"key":"2768_CR52","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin, M. et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J. Thorac. Oncol. 14, 1784\u20131793 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2768_CR53","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan, A. B. et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 47, W212\u2013W224 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2768_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan, Y. et al. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat. Genet. 57, 126\u2013139 (2025).","journal-title":"Nat. Genet."},{"key":"2768_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02074-6","volume":"10","author":"KH Prazanowska","year":"2023","unstructured":"Prazanowska, K. H. & Lim, S. B. An integrated single-cell transcriptomic dataset for non-small cell lung cancer. Sci. Data 10, 167 (2023).","journal-title":"Sci. Data"},{"key":"2768_CR56","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"WA Freed-Pastor","year":"2021","unstructured":"Freed-Pastor, W. A. et al. The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39, 1342\u20131360 (2021).","journal-title":"Cancer Cell"},{"key":"2768_CR57","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"2768_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1101\/gad.1165104","volume":"18","author":"MI Koster","year":"2004","unstructured":"Koster, M. I., Kim, S., Mills, A. A., DeMayo, F. J. & Roop, D. R. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 18, 126\u2013131 (2004).","journal-title":"Genes Dev."},{"key":"2768_CR59","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cell.2007.02.045","volume":"129","author":"M Senoo","year":"2007","unstructured":"Senoo, M., Pinto, F., Crum, C. P. & McKeon, F. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129, 523\u2013536 (2007).","journal-title":"Cell"},{"key":"2768_CR60","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1097-2765(00)80275-0","volume":"2","author":"A Yang","year":"1998","unstructured":"Yang, A. et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305\u2013316 (1998).","journal-title":"Mol. Cell"},{"key":"2768_CR61","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1242\/dev.02325","volume":"133","author":"J Laurikkala","year":"2006","unstructured":"Laurikkala, J. et al. p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 133, 1553\u20131563 (2006).","journal-title":"Development"},{"key":"2768_CR62","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.immuni.2018.09.020","volume":"49","author":"G Mollaoglu","year":"2018","unstructured":"Mollaoglu, G. et al. The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment. Immunity 49, 764\u2013779 (2018).","journal-title":"Immunity"},{"key":"2768_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.devcel.2018.02.024","volume":"44","author":"PR Tata","year":"2018","unstructured":"Tata, P. R. et al. Developmental history provides a roadmap for the emergence of tumor plasticity. Dev. Cell 44, 679\u2013693 (2018).","journal-title":"Dev. Cell"},{"key":"2768_CR64","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2016.09.001","volume":"30","author":"G Ferone","year":"2016","unstructured":"Ferone, G. et al. SOX2 Is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell 30, 519\u2013532 (2016).","journal-title":"Cancer Cell"},{"key":"2768_CR65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.celrep.2016.12.059","volume":"18","author":"AS Nagaraj","year":"2017","unstructured":"Nagaraj, A. S. et al. Cell of origin links histotype spectrum to immune microenvironment diversity in non-small-cell lung cancer driven by mutant Kras and loss of Lkb1. Cell Rep. 18, 673\u2013684 (2017).","journal-title":"Cell Rep."},{"key":"2768_CR66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.stem.2009.04.002","volume":"4","author":"EL Rawlins","year":"2009","unstructured":"Rawlins, E. L. et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 4, 525\u2013534 (2009).","journal-title":"Cell Stem Cell"},{"key":"2768_CR67","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-9440(10)63147-1","volume":"164","author":"KU Hong","year":"2004","unstructured":"Hong, K. U., Reynolds, S. D., Watkins, S., Fuchs, E. & Stripp, B. R. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am. J. Pathol. 164, 577\u2013588 (2004).","journal-title":"Am. J. Pathol."},{"key":"2768_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32052-2","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Club cells employ regeneration mechanisms during lung tumorigenesis. Nat. Commun. 13, 4557 (2022).","journal-title":"Nat. Commun."},{"key":"2768_CR69","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41588-022-01177-x","volume":"54","author":"JT Lange","year":"2022","unstructured":"Lange, J. T. et al. The evolutionary dynamics of extrachromosomal DNA in human cancers. Nat. Genet. 54, 1527\u20131533 (2022).","journal-title":"Nat. Genet."},{"key":"2768_CR70","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41568-024-00669-8","volume":"24","author":"X Yan","year":"2024","unstructured":"Yan, X., Mischel, P. & Chang, H. Extrachromosomal DNA in cancer. Nat. Rev. Cancer 24, 261\u2013273 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2768_CR71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume":"343","author":"DA Nathanson","year":"2014","unstructured":"Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343, 72\u201376 (2014).","journal-title":"Science"},{"key":"2768_CR72","doi-asserted-by":"publisher","first-page":"eadj1415","DOI":"10.1126\/science.adj1415","volume":"383","author":"EE Gardner","year":"2024","unstructured":"Gardner, E. E. et al. Lineage-specific intolerance to oncogenic drivers restricts histological transformation. Science 383, eadj1415 (2024).","journal-title":"Science"},{"key":"2768_CR73","doi-asserted-by":"publisher","unstructured":"Di Federico, A. et al. TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors. J. Thorac. Oncol. 21, 103610 https:\/\/doi.org\/10.1016\/j.jtho.2026.103610 (2026).","DOI":"10.1016\/j.jtho.2026.103610"},{"key":"2768_CR74","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","volume":"31","author":"F Skoulidis","year":"2025","unstructured":"Skoulidis, F. et al. Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer. Nat. Med. 31, 2755\u20132767 (2025).","journal-title":"Nat. Med."},{"key":"2768_CR75","doi-asserted-by":"publisher","first-page":"eaea4881","DOI":"10.1126\/scitranslmed.aea4881","volume":"18","author":"A Dymun","year":"2026","unstructured":"Dymun, A. et al. Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation. Sci. Transl. Med. 18, eaea4881 (2026).","journal-title":"Sci. Transl. Med."},{"key":"2768_CR76","doi-asserted-by":"publisher","first-page":"baz046","DOI":"10.1093\/database\/baz046","volume":"2019","author":"O Franz\u00e9n","year":"2019","unstructured":"Franz\u00e9n, O., Gan, L.-M. & Bj\u00f6rkegren, J. L. M. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database 2019, baz046 (2019).","journal-title":"Database"},{"key":"2768_CR77","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1101\/gad.349659.122","volume":"36","author":"S Naranjo","year":"2022","unstructured":"Naranjo, S. et al. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev. 36, 936\u2013949 (2022).","journal-title":"Genes Dev."},{"key":"2768_CR78","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature13906","volume":"516","author":"FJ S\u00e1nchez-Rivera","year":"2014","unstructured":"S\u00e1nchez-Rivera, F. J. et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428\u2013431 (2014).","journal-title":"Nature"},{"key":"2768_CR79","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1101\/gad.14.8.994","volume":"14","author":"S Marino","year":"2000","unstructured":"Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994\u20131004 (2000).","journal-title":"Genes Dev."},{"key":"2768_CR80","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt, R. J. et al. CRISPR\u2013Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440\u2013455 (2014).","journal-title":"Cell"},{"key":"2768_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"2768_CR82","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2768_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2768_CR84","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).","journal-title":"Bioinformatics"},{"key":"2768_CR85","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"2768_CR86","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-018-0368-6","volume":"33","author":"MA Loberg","year":"2019","unstructured":"Loberg, M. A. et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia 33, 1635\u20131649 (2019).","journal-title":"Leukemia"},{"key":"2768_CR87","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"2768_CR88","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"2768_CR89","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"2768_CR90","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"2768_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08831-9","volume":"10","author":"I Angelidis","year":"2019","unstructured":"Angelidis, I. et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat. Commun. 10, 963 (2019).","journal-title":"Nat. Commun."},{"key":"2768_CR92","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41586-024-07113-9","volume":"627","author":"G Han","year":"2024","unstructured":"Han, G. et al. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 627, 656\u2013663 (2024).","journal-title":"Nature"},{"key":"2768_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17358-3","volume":"11","author":"M Strunz","year":"2020","unstructured":"Strunz, M. et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. Nat. Commun. 11, 3559 (2020).","journal-title":"Nat. Commun."}],"container-title":["Nature Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02768-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02768-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:03:51Z","timestamp":1791482631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41588-026-02768-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2768"],"URL":"https:\/\/doi.org\/10.1038\/s41588-026-02768-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7058952\/v1","asserted-by":"object"}]},"ISSN":["1061-4036","1546-1718"],"issn-type":[{"value":"1061-4036","type":"print"},{"value":"1546-1718","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.M.A. has served as an ad hoc consultant for Longitude Capital on matters unrelated to the content of this manuscript. D.Y. is a co-founder and consultant for DEM Biopharma. T.J. is a member of the board of directors of Amgen and Thermo Fisher Scientific, a co-founder of Dragonfly Therapeutics, T2 Biosystems and Novello Therapeutics. Amgen currently owns and markets sotorasib, the primary therapeutic compound used in this manuscript. Sotorasib was purchased from a third-party source, Selleck Chemicals, and the work was not performed as a sponsored research agreement. T.J. serves on the scientific advisory board of Skyhawk Therapeutics and is the president of\n                      Break Through Cancer\n                      . The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}